Clinical trial

A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers

BrainCells Inc.CompletedPhase 1Started Oct 1, 201131 enrolledNetherlandsNCT01546051

Abstract

This study will evaluate the safety, tolerability and pharmacokinetics of BCI-838, its metabolite BCI-632 and several new pro-drugs in healthy male subjects.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

KetamineDepression

Keywords

metabotropic glutamate receptors 2 and 3antagonistmGluRBDNFMajor Depressive DisorderMood DisorderTreatment Resistant DepressionPhase 1 safety, tolerability and pharmacokinetics studyHealthy

View on registry

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

Related research

ArticleKetamine

Pharmacologic Approaches to Suicide Prevention.

Zisook S, Domingues I, Compton J

Europe PMC2023

ArticleKetamine

Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature.

Drozdz SJ, Goel A, McGarr MW +6

Europe PMC2022

ArticleKetamine

Effects of ketamine on individual symptoms and symptom networks of depression in a randomised controlled trial of ketamine for treatment-resistant depression.

Hossein S, Rengasamy M, Uzamere A +5

Europe PMC2025